Novartis' determined commitment to biomedical innovation to improve the quality of life of people in fields such as oncology, cardiology, neurology and immunology was reflected last night in the event “Passionate about science and people”. An event attended by more than 100 attendees, among whom were patient associations, representatives of scientific societies, hospital centers, research groups, public administration and the media.
The meeting, which began with an institutional opening by Ana Ramírez de Molina, Vice-Minister of Universities, Research and Science of the Community of Madrid, and was closed by Eva Ortega-Paíno, General Secretary of Research of the Ministry of Science, Innovation and Universities; highlighted the need to work together to reimagine medicine. As Jesús Ponce, president of Novartis Spain, pointed out in his speech: “If there is no science there is no therapeutic innovation, without therapeutic innovation there is no improvement in health, if there is no improvement in health there is no life, and without life, There are no people."
Currently, Novartis is developing innovative medicines by taking advantage of its capabilities in 3 advanced technological platforms with great therapeutic potential: gene and cell therapies, RNA technology and radioligand therapies (TRL). All this, added to the continuity of the company's work in the two most established research platforms: chemical and biological therapies.
The characteristics of these platforms, which bring us closer to a model of precision medicine with great transformative potential, were presented by the biologist, doctor in biomedical biotechnology and scientific disseminator Ricardo Moure and experts such as Dr. José Luis Zamorano (Chief of the Cardiology Service of the Ramón y Cajal Hospital) and Dr. Adolfo Gómez (Head of the Nuclear Medicine Service Hospital 12 de Octubre).
Subsequently, the round table “The 3 Cs: united to generate Commitment, Trust and Collaboration of impact” was held, which included the participation of Dr. Rosario Perona, head of the Support Unit for the General Directorate of the Institute of Health Carlos III (ISCIII); Dr. José María de la Torre Hernández, vice president of the Spanish Society of Cardiology (SEC), Dr. Yolanda Gilaberte, president of the Spanish Academy of Dermatology and Venereology (AEDV), Carina Escobar, president of the Platform of Cardiology Organizations Patients (POP); and José Manuel González Huesa, general director of Servimedia.
Among the main conclusions, they highlighted the need to promote greater patient participation in decision-making, the urgency of offering reliable sources of information and collaborating in scientific dissemination, and the importance of creating synergies between health agents.
The last intervention was led by Margarita Álvarez, scientific communicator and director of the Human Age Institute, named by Forbes magazine as one of the 50 most powerful women in Spain and one of the 100 most influential women in Spain for three consecutive years.
